ParticipantsAbraham Kessler, BA, Bronx, NY (Abstract Co-Author) Nothing to Disclose
Robert Peng, MD, Bronx, NY (Presenter) Nothing to Disclose
Edward Mardakhaev, MD, Bronx, NY (Abstract Co-Author) Nothing to Disclose
Charles S. White, MD, Baltimore, MD (Abstract Co-Author) Consultant, Koninklijke Philips NV
Linda B. Haramati, MD, MS, Bronx, NY (Abstract Co-Author) Spouse, Board Member, Kryon Systems Ltd
kessler.abraham@gmail.com
PURPOSETo compare the performance of the Vancouver Risk Calculator (VRC) with ACR Lung-RADS for a lung cancer screening cohort in an urban, diverse clinical setting.
METHOD AND MATERIALSIRB approval was obtained. All lung cancer screening patients who had their initial screening CT from December 2012-June 2016 demonstrating a nodule comprised the study population. Each exam was assigned a Lung-RADS score, with 4A and 4B considered positive. The VRC calculates the risk of cancer at different thresholds using 9 patient and imaging variables, with a 5% threshold considered positive. Analysis was performed on a per-patient level based on the largest nodule. Follow-up information was obtained via EMR, cancer registry and NDI. Patients with initial studies suspicious for malignancy but without histologic confirmation were adjudicated on a case-by-case basis. Performance characteristics to predict lung cancer were compared for Lung-RADS and VRC.
RESULTS486 patients, 261(53.7%) women, mean age 63±5.2, comprised the study population. Mean follow-up time was 36.9± 11.1 months, and 61(12.6%) patients were lost to follow-up. Lung cancer was diagnosed in 35(7.2%). Lung-RADS had 10 FP and 14 FN while VRC 5% had 30 FP and 8 FN. Overall sensitivity, specificity and accuracy for Lung-RADS was 61.1%, 97.8%, and 94.9% and for VRC 5% was 77.8%, 93.3%, and 92.2%, respectively.
CONCLUSIONIn comparison with Lung-RADS, the VRC demonstrated higher sensitivity but lower specificity and accuracy in predicting malignancy among patients in a diverse clinical lung cancer screening program.
CLINICAL RELEVANCE/APPLICATIONLungRADS and VRC achieved complementary results in a diverse urban clinical lung cancer screening program. Use of the two, in concert, may improve lung cancer prediction.